NATUS Neurology has secured regulatory clearances in the US and Canada for its new nerve conduction device, the UltraPro S100 EMG system.

The system is used to monitor and test electrophysiologic and electrodiagnostic information from a patient’s nervous and muscular systems. It received 510(K) clearance from the US Food and Drug Administration and approval from Health Canada.

The UltraPro S100 offers efficient connectivity to electronic medical records and online summaries and a built-in reference value database.

Natus vice president and general manager Austin Noll said: "The UltraPro S100 helps strengthen our market-leading EMG portfolio and ensures clinicians and patients can benefit from the latest advancements in neurological care."

Following inputs from neurologists and electrodiagnostic technicians, the device was designed in order to improve workflow effectively by organising the data into several automated reporting formats, especially for busy clinical settings.

The system also enables clinicians to finish studies and produce reports with ease, helping to streamline workflow, improve efficiency and reduce costs.

Over the next year, Natus plans to present the system at leading trade shows in the US and Canada.

The company provides healthcare products that are used for the screening, detection, treatment, monitoring and tracking of common ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders and balance and mobility disorders.